US-based medtech company Axonics have received FDA approval for their fourth-generation, rechargeable sacral neuromodulation system for the treatment of chronic incontinence.
Axonics R20 is an implantable device which lasts for 20 years and only needs charging every six to ten months for one hour ‒ its third-generation R15 needed charging once a month for one hour. This improvement was made so patients could have an improved quality of life without concerns over the device’s battery life.
